The concentration of IL-6 was higher in patients with more advanced stage of carcinoma, as evidenced by the significantly greater difference in the concentration levels of this cytokine in patients in the BCLC B group compared to those in the BCLC A and cirrhosis (tumor-free) groups. This evidence concerns the gene IL6 and carcinoma.